info@marketresearchfuture.com   📞  +1 (855) 661-4441(US)   📞  +44 1720 412 167(UK)
Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players’ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Cardiac Valve Market Share

ID: MRFR//0117-HCR | 110 Pages | Author: Kinjoll Dey| November 2024

Because it treats various heart problems, the cardiac valve market is crucial for the medical device industry. Strategic market positioning helps heart valve manufacturers stand out and beat their competitors. We'll examine the most crucial cardiac valve market share techniques below.
Market placement requires a variety of cardiac valves. In order to satisfy all customers, firms make mechanical, biological, and transcatheter valves. With so many alternatives, doctors can choose valves for each patient and procedure.
Staying ahead of new innovations is crucial to positioning the cardiac valve industry. Companies invest in R&D to develop safe materials, longer-lasting goods, and improved transcatheter valve delivery systems. Tech keeps improving, so products meet shifting heart care standards.
They emphasize minimally invasive technologies, including transcatheter valves, to compete. Valve manufacturers make less-invasive therapies, reducing open-heart procedures. This focus matches the medical field's tendency toward minimally invasive procedures, making the goods easier to buy.
Valve customization for different patients is clever. Companies create valves in various sizes and shapes to fit clients' bodies. Customization lets doctors get valves that fit each patient's heart structure, improving results.
Valve manufacturing with biocompatible materials is strategic market positioning. Companies are researching materials that minimize responses, thrombosis, and hardening. Modern materials improve heart valve performance and lifespan, making them more competitive.
Upholding moral standards and following regulators' guidelines is crucial in the heart valve business. Quality assurance means companies ensure their valves meet or exceed government requirements. This guarantee ensures patient safety and offers healthcare practitioners and regulators confidence in the valves.
Building solid ties with healthcare institutions is key to market positioning. Working with hospitals, heart centers, and heart specialists can help companies understand changing patient needs, test their products, and build medical trust in their heart valves.
Globalization is necessary for heart valve manufacturers to compete. This requires navigating multiple legal frameworks, adapting products to regional demands, and developing a strong distribution network. Global companies can meet more requirements and seize new opportunities.
Teaching and educating heart valve users costs companies money. Workshops, training, and educational materials promote each valve type's benefits and proper use. Doctors and other health care providers' training simplifies product use.
Healthcare is cost-sensitive, thus competitive and clear price models are essential. Companies aim to balance selling high-quality heart valves at reasonable prices for doctors. Competitive pricing opens more markets and attracts more customers.
Participating in clinical trials is wise. Companies conduct clinical studies to prove their heart valves are safe and effective. Good trial findings help regulators approve medicines, build medical professional credibility, and differentiate items.
Asking doctors for feedback and using it to improve the product is clever. Heart valve manufacturers that constantly develop based on consumer feedback make them better and easier to use. This iterative procedure adapts products to surgical preferences and methods.

Covered Aspects:

Report Attribute/Metric Details
Base Year For Estimation 2023
Forecast Period 2024-2032
Growth Rate 5.62% (2024-2032)

Global Cardiac Valve Market Overview


Cardiac Valve Market Size was valued at USD 7.7 Billion in 2023. The Cardiac Valve market industry is projected to grow from USD 8.20 Billion in 2024 to USD 12.7 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.62% during the forecast period (2024 - 2032). The burden of valvular heart disease is increasing, and individuals are living more sedentary lifestyles, are the key market drivers enhancing the market growth.


Cardiac Valve Market


Source Secondary Research, Primary Research, MRFR Database and Analyst Review


Cardiac Valve Market Trends



  • Rise in burden exerted by valvular heart diseases is driving the market growth


Increased geriatric population, shift in people's lifestyles from active to sedentary, novel developments in heart valves, increased awareness of surgical treatment options, and rising demand for minimally invasive surgeries are all factors driving the market's expansion. For instance, the American College of Cardiology estimates that every year, heart valve disease affects about 5 million Americans. However, some of the key constraints inhibiting the market's growth include the high cost of cardiac valves and the availability of other solutions for treating heart valve illness. Another significant factor influencing the heart valve repair and replacement market is the ability of computational tools to mimic additional fluid mechanics properties like pressure decreases, regurgitation volumes, or turbulence. Additionally, the availability of computational techniques enables precise diagnosis of valvar illness, which results in effective therapy and expands the market for cardiac valve repair and replacement.


The market for Cardiac Valve devices and equipment has been driven by the growing demand for transcatheter aortic valve replacement (TAVR) procedures as the prevalence of valvular heart disease has increased. The aortic valve of the heart is impacted by the valvular heart ailment known as aortic stenosis. A minimally invasive surgical procedure used to treat it is called TAVR. The aortic valve stiffens as a result of aortic stenosis, obstructing normal blood flow. The damaged aortic valve is replaced using a transcatheter valve. The Society of Thoracic Surgeons (STS)/American College of Cardiology (ACC) TVT Registry study found that volumes had risen annually. 2019 marked the first year that TAVR overcame all variations of surgical aortic valve replacement (SAVR). The number of TAVR performed each year is rising in accordance with the FDA's clearance of the procedure for low-risk patients, and in 2019 the overall volume of TAVR (72,991) surpassed all other types of SAVR (57,626). The frequency of TAVR surgeries will probably increase along with the prevalence of valvular heart disease, which will lead to a rise in the demand for transcatheter valves and, in turn, a rise in the market for cardiac valves.


The rising incidence of heart valve illness and the rising number of novel and improved cardiac valves receiving regulatory approvals are the key drivers driving the market's expansion. The market is expanding as a result of the rising incidence of heart valve disease, which is a significant component. For instance, rheumatic heart disease affects 39 million people worldwide, according to the World Heart Federation 2022. It is a condition when rheumatic fever has permanently affected the heart valves. Thus, driving the Cardiac Valve market revenue.


Cardiac Valve Market Segment Insights


Cardiac Valve Treatment Insights


The  Cardiac Valve market segmentation, based on Treatment, includes cardiac wall repair, cardiac wall replacement and others. Cardiac wall repair segment dominated the  market in 2022. The increasing prevalence of cardiovascular diseases can be blamed for this.


Cardiac Valve Type Insights


The  Cardiac Valve market segmentation, based on Type, includes mechanical valves, tissue/bioprosthetic valves, transcatheter heart valves/percutaneous heart valves, and others. The tissue/bioprosthetic valves segment dominated the  market in 2022. The market share of the mechanical valve segment is being constrained by the dominance of the tissue valve market due to the advent of bioprosthetic valves and their advantages, which include strength, flexibility, and a reduced need for anticoagulants. Other valves will also have steady growth over the forecasted time.


Cardiac Valve Position Insights


The  Cardiac Valve market segmentation, based on Position, includes mitral valve, aortic valve, and other position. Mitral valve segment dominated the  cardiac valve market in 2022. This is because cardiovascular disease is becoming more common as a result of factors including smoking, obesity, inactivity, and other stressors on the cardiovascular system.


Cardiac Valve End User Insights


The  Cardiac Valve market segmentation, based on End User, includes hospital & clinics, specialty centers, cardiac research institute, and others. The hospital & clinics segment dominated the  Cardiac Valve market in 2022. This is because of better government spending, an increase in hospital procedures, and better vulvar disease management. Cardiac Valve Market Value is developing as a result of specialty clinics, as well as other market sectors.


Figure 1  Cardiac Valve Market, by End User, 2022 & 2032 (USD Billion)Cardiac Valve Market, by End User, 2022 & 2032


Source Secondary Research, Primary Research, MRFR Database and Analyst Review


Cardiac Valve Regional Insights


By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North America Cardiac Valve Market dominated this market in 2022 (45.80%). This is due to an increase in medical knowledge, new product introductions, and regulatory rules that make it simple to produce and maintain heart valve devices. In addition, the rising frequency of lifestyle diseases like diabetes and obesity is a significant component in the region's domination. Further, the U.S. Cardiac Valve market held the largest market share, and the Canada Cardiac Valve market was the fastest growing market in the North America region.


Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.


Figure 2  CARDIAC VALVE MARKET SHARE BY REGION 2022 (USD Billion)CARDIAC VALVE MARKET SHARE BY REGION 2022


Source Secondary Research, Primary Research, MRFR Database and Analyst Review


Europe Cardiac Valve market accounted for the healthy market share in 2023. The high frequency of heart valve problems, product improvements, the volume of heart valve replacement surgeries, and the well-established healthcare infrastructure are the main drivers of the market's growth. Further, the German Cardiac Valve market held the largest market share, and the U.K Cardiac Valve market was the fastest growing market in the European region


The Asia Pacific Cardiac Valve market is expected to register significant growth from 2024 to 2032. This is because aortic stenosis and other cardiac illnesses are becoming more common, healthcare infrastructure is increasing in places like China and India, and industry participants are constantly looking for opportunities to invest in new markets. For instance, aortic stenosis is thought to affect 1 in 8 geriatric Australians, according to information provided by Hope for Hearts. Additionally, it was calculated that at least 97,000 Australians over the age of 55 suffer from severe aortic stenosis (AS). Moreover, China’s Cardiac Valve market held the largest market share, and the Indian Cardiac Valve market was the fastest growing market in the Asia-Pacific region.


Cardiac Valve Key Market Players & Competitive Insights


Leading market players are investing heavily in research and development in order to expand their product lines, which will help the Cardiac Valve market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their  footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, Cardiac Valve industry must offer cost-effective items.


Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the  Cardiac Valve industry to benefit clients and increase the market sector. In recent years, the Cardiac Valve industry has offered some of the most significant advantages to medicine. Major players in the Cardiac Valve market, including Medtronic, Edwards Lifesciences Corporation, Boston Scientific Corporation, LivaNova PLC, Abbott, CryoLife, Inc, On-X Life Technologies, Inc., Colibri Heart Valve, JenaValve Technology, Inc., and TTK HealthCare, are attempting to increase market demand by investing in research and development Products.


An organisation that develops, produces, and markets devices for structural heart disease, critical care, and surgical monitoring is called Edwards Lifesciences Corp (Edwards Lifesciences). The company sells transcatheter heart valves, pressure monitoring equipment, hemodynamic monitoring equipment, surgical valve replacement and repair devices, as well as other tools and accessories. The management of clotting, hypotension, and sepsis, as well as transcatheter aortic valve replacement (TAVR), blood conservation, infection control, and improved surgical recovery are just a few therapies that its products are used in. The business sells its goods directly to consumers as well as through a network of independent distributors in regions like North America, Europe, and Asia-Pacific. The American city of Irvine serves as the headquarters of Edwards Lifesciences. The MITRIS RESILIA valve was approved by the US Food and Drug Administration (FDA) in March 2022 for Edwards Lifesciences. It is a tissue valve replacement made especially for the mitral location of the heart.


The mission of JenaValve Technology, Inc., a developer and producer of transcatheter aortic valve replacement (TAVR) systems, is to enhance the quality of life for people with structural heart diseases. Because of an anatomically based locator fixation and dual sealing valve design, the company's technology uses porcine pericardial tissue and a self-expanding nitinol frame with a transfemoral delivery system that does not require rapid pacing. This enables patients with ease of use, decreased risks of paravalvular regurgitation, and durability of hemodynamic results. With the Chinese company Peijia Medical Limited, JenaValve Technology, Inc. engaged into a strategic investment and exclusive technology licencing deal in January 2022.


Key Companies in the Cardiac Valve market include



  • Medtronic

  • Edwards Lifesciences Corporation

  • Boston Scientific Corporation

  • LivaNova PLC

  • Abbott

  • CryoLife, Inc

  • On-X Life Technologies, Inc.

  • Colibri Heart Valve

  • JenaValve Technology, Inc.

  • TTK HealthCare


Cardiac Valve Industry Developments


September 2019 Transcatheter aortic valve replacement (TAVR) system Evolut PRO+ has been made available in the United States, according to Medtronic.


September 2019 TriClip, a transcatheter tricuspid valve repair for the treatment of tricuspid regurgitation, was the subject of the TRILUMINATE pivotal trial that was started by Abbott.


Cardiac Valve Market Segmentation


Cardiac Valve Treatment Outlook



  • Cardiac Wall Repair

  • Cardiac Wall Replacement

  • Others


Cardiac Valve Type Outlook



  • Mechanical Valves

  • Tissue/Bioprosthetic Valves

  • Transcatheter Heart Valves/Percutaneous Heart Valves

  • Others


Cardiac Valve Position Outlook



Cardiac Valve End User Outlook



  • Hospital & Clinics

  • Specialty Centers

  • Cardiac Research Institute

  • Others


Cardiac Valve Regional Outlook



  • North America

    • US

    • Canada



  • Europe

    • Germany

    • France

    • UK

    • Italy

    • Spain

    • Rest of Europe



  • Asia-Pacific

    • China

    • Japan

    • India

    • Australia

    • South Korea

    • Australia

    • Rest of Asia-Pacific



  • Rest of the World

    • Middle East

    • Africa

    • Latin America



Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Kindly complete the form below to receive a free sample of this Report
Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.